...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on medical diagnostics. >Multianalyte assay systems in the differential diagnosis of ovarian cancer
【24h】

Multianalyte assay systems in the differential diagnosis of ovarian cancer

机译：多种分析物测定系统在卵巢癌的鉴别诊断中

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The efficient triage of women diagnosed with a pelvic mass presents currently an area of unmet need. Unnecessary surgical intervention performed on patients at a decreased risk of malignancy represents a significant source of preventable morbidity, anxiety and cost. Likewise, delayed or overlooked referral of patients harboring malignant tumors is strongly associated with diminished outcomes. Current tools including imaging modalities and the CA 125 blood test are of insufficient accuracy to overcome these challenges. The use of multianalyte assay systems, which include additional biomarkers capable of complementing the performance of CA 125, may offer the best hope of improvement. Areas covered: Recent findings regarding the use of multianalyte biomarker panels for the differential diagnosis of a pelvic mass are reviewed and discussed. Particular attention is paid to the FDA-approved ROMA and OVA1 tests. The development, validation, recent evaluation and comparative performances of these two tests are reviewed in detail. Expert opinion: The performances achieved by the ROMA and OVA1 diagnostic tests represent significant milestones in the application of multianalyte assay systems into standard clinical practice. The overall impact and cost-effectiveness of widespread clinical use of these tools remain to be evaluated.
机译：简介：目前，诊断出骨盆肿块的妇女的有效分流是目前尚未满足的领域。对恶性肿瘤风险降低的患者进行不必要的手术干预是可预防的发病率，焦虑和成本的重要来源。同样，患有恶性肿瘤的患者转诊延迟或被忽视与转归减少密切相关。当前的工具（包括成像模式和CA 125血液测试）的准确性不足以克服这些挑战。多分析物测定系统的使用，其中包括能够补充CA 125性能的其他生物标记物，可能会带来改善的最大希望。涵盖领域：审查和讨论有关使用多分析物生物标志物组进行盆腔肿块鉴别诊断的最新发现。特别要注意FDA批准的ROMA和OVA1测试。对这两个测试的开发，验证，最新评估和比较性能进行了详细的回顾。专家意见：ROMA和OVA1诊断测试获得的性能代表了将多分析物测定系统应用于标准临床实践中的重要里程碑。这些工具的广泛临床使用的总体影响和成本效益仍有待评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号